Identity
What it answers
Is the mass of the main component consistent with the peptide you have named? The report can set the observed mass against the mass calculated from the stated sequence, with the error in parts per million.
Testing
GS Laboratory offers independent analytical testing of peptides and other pharmaceutical products. We do not manufacture or sell peptides or medicines. The tests below describe the question each method is intended to answer. Methods, reporting limits and the exact panel are agreed before work begins.
Family A
Typical submissions are a lyophilized powder or a solution, in one or more vials. Endotoxin and sterility, where requested, usually require their own unopened containers.
What it answers
Is the mass of the main component consistent with the peptide you have named? The report can set the observed mass against the mass calculated from the stated sequence, with the error in parts per million.
What it answers
What proportion of the UV peak area is the main peak, and what related substances are visible under the method used? Integration settings and, where agreed, the chromatogram itself can be included in the report.
What it answers
How much peptide is present in the vial or in the sample as received? Content is a separate question from chromatographic purity: a pure main peak does not, on its own, state how many milligrams are in the container.
What it answers
What level of bacterial endotoxin is measured in the sample, using a Limulus amoebocyte lysate method? This test is reported only when it has been requested and a suitable container has been provided.
What it answers
Does the sample meet the sterility test described in USP <71>, which requires a defined incubation period? Where the method requires it, a separate unopened container is used. The report states whether the test was performed.
What it answers
Are residual organic solvents present, and at what levels, under the method used? The solvents of interest are agreed with the submission.
What it answers
Which counter-ion is present — for example trifluoroacetate or acetate — and in what proportion of the material as received?
What it answers
How much water is in the powder or material as received?
What it answers
When more than one vial from the same group is tested, how closely do the selected vials agree? The number of vials and the attributes compared are agreed in advance.
Family B
Raw materials and finished products can be examined with a comparable quality-control approach. The exact panel depends on the dosage form and the questions asked.
What it answers
How much of the stated active substance is present, relative to the label or to an agreed specification?
What it answers
What organic impurities or degradation products are detected, and at what levels, under the method used?
What it answers
Are specified elemental impurities present, and do the measured levels remain within the limits that have been set for the material or product?
What it answers
Are residual organic solvents present in the material, and at what levels, under the method used?
What it answers
Do total aerobic microbial counts, and yeast and mould counts, remain within the agreed limits for the sample type?
What it answers
For products that require it, does the sample meet a sterility test such as the procedure in USP <71>? The report states the method and the outcome.
What it answers
What endotoxin level is measured, where this test applies to the product or material?
What it answers
For solid oral dosage forms and other preparations, does the product release the active substance in the manner described by the relevant test, or meet another official-style procedure that has been agreed in advance? These tests are discussed at the method level before work begins.
Not every test is performed on every sample. A short written scope is confirmed with each submission so the report only contains work that was actually carried out.